Lyophilized Vials (reconstitution required)

Compounded Medication – Prescription Only

This product is a compounded injectable preparation containing insulin-like growth factor-1 long R3 (IGF-1 LR3), supplied as lyophilized (freeze-dried) vials and dispensed only pursuant to a valid prescription issued by a licensed healthcare provider. IGF-1 LR3 is a synthetic peptide analogue structurally related to naturally occurring insulin-like growth factor-1. In compounding practice, peptide formulations may be prescribed when a provider determines that individualized formulation, concentration, or vial configuration considerations are clinically appropriate for a specific patient. This product is not available for self-selection and may only be dispensed following provider authorization. Compounded medications are not approved by the U.S. Food and Drug Administration (FDA). The FDA does not evaluate compounded formulations for safety, effectiveness, or quality. Compounding is performed by a state-licensed pharmacy pursuant to a patient-specific prescription. This page provides general, non-therapeutic information for educational and compliance purposes only. It does not describe intended use, therapeutic benefit, physiologic effect, performance outcomes, or expected clinical results.

General Scientific Information (Non-Therapeutic)

IGF-1 LR3 is a laboratory-synthesized peptide analogue modified for extended molecular stability and altered receptor-binding characteristics compared to endogenous IGF-1. Scientific literature references its amino acid sequence, molecular structure, and biochemical properties studied in laboratory and controlled research environments. Descriptions of molecular characteristics are provided solely for general scientific context. No claims are made regarding safety, effectiveness, anabolic effects, metabolic outcomes, or suitability for any particular condition.

Contraindications

IGF-1 LR3 injection should not be used in individuals who have a known hypersensitivity or allergy to IGF-1 LR3, peptide-based compounds, or any component of the compounded formulation; have experienced prior adverse reactions to injectable peptide preparations; have active malignancy or other conditions in which growth factor exposure is contraindicated as determined by the prescribing healthcare provider; or are unable to tolerate injectable therapies. Use in pregnant or breastfeeding individuals should occur only if a licensed healthcare provider determines that potential risks and benefits have been carefully evaluated.

Warnings and Precautions

Peptide-based injectable formulations may produce systemic effects. Caution is advised in individuals with endocrine disorders, glucose regulation abnormalities, cardiovascular disease, or those receiving medications that affect metabolic or hormonal pathways. Injectable administration should be performed only as prescribed and supervised by a licensed medical provider. Patients should inform their healthcare provider of all medical conditions, medications, and supplements prior to receiving this compounded formulation.

Potential Side Effects

Reported side effects associated with injectable peptide formulations may include injection site reactions such as pain, redness, swelling, or irritation; headache; dizziness; nausea; fatigue; edema; or transient changes in glucose regulation. Serious adverse reactions are uncommon but may occur. Patients should seek immediate medical attention if they experience signs of a severe allergic reaction or unexpected systemic symptoms.